Morrisville, N.C., April 1, 2021 Premier Research, the clinical research company that delivers outcome-focused insights which support sponsors in developing life-changing therapies, today announced that it has acquired Bangalore, India-based Cytespace to expand its global organizational footprint. The acquisition will provide Premier Research’s biotech and specialty pharma sponsors with enhanced operational support in areas such as data management, document management, study start-up, and regulatory operations.
This acquisition firmly integrates the Cytespace team into Premier Research’s global clinical development efforts, giving Premier’s innovative customers access to Cytespace’s extensive experience with a strong patient-centric research model in India. The deal also provides customers with support for large-scale, late-phase, and non-interventional global studies where the collection and analysis of substantial amounts of data is critical.
“With more clinical trials seeking to enroll diverse and global patient populations, our acquisition of Cytespace will allow Premier Research to support our customers at the highest level of competency in the region, providing even greater access to patients,” said Premier Research CEO, Ludo Reynders. “We’ve conducted many trials in Asia-Pacific, and the combination of Premier Research and Cytespace positions both entities for powerful growth in this rapidly expanding market.”
For more information, visit www.cytespace.com.
About Premier Research
Premier Research, a clinical research company, is dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments.
As a global company, Premier Research specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors.
Whether it’s developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier Research is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions.